260 related articles for article (PubMed ID: 29927180)
1. Renal Protective Effects of Combination of Diltiazem and ACEI/ARB on the Progression of Diabetic Nephropathy: Randomized Controlled Trial.
Krairittichai U; Sarinnapakorn V; Mahannopkul R; Ainwan P
J Med Assoc Thai; 2017 Feb; 100 Suppl 1():S40-7. PubMed ID: 29927180
[TBL] [Abstract][Full Text] [Related]
2. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
3. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
Saklayen MG; Gyebi LK; Tasosa J; Yap J
J Investig Med; 2008 Apr; 56(4):714-9. PubMed ID: 18382267
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?
Hilgers KF; Dötsch J; Rascher W; Mann JF
Pediatr Nephrol; 2004 Sep; 19(9):956-61. PubMed ID: 15278690
[TBL] [Abstract][Full Text] [Related]
7. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Mavrakanas TA; Gariani K; Martin PY
Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Rossing K; Jacobsen P; Pietraszek L; Parving HH
Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
[TBL] [Abstract][Full Text] [Related]
10. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial.
Titan SM; M Vieira J; Dominguez WV; Barros RT; Zatz R
Clin Nephrol; 2011 Oct; 76(4):273-83. PubMed ID: 21955862
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic management of diabetic nephropathy.
Vivian EM; Rubinstein GB
Clin Ther; 2002 Nov; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
[TBL] [Abstract][Full Text] [Related]
12. Slowing the progression of renal disease in diabetic patients.
Vivian EM; Goebig ML
Ann Pharmacother; 2001 Apr; 35(4):452-63. PubMed ID: 11302410
[TBL] [Abstract][Full Text] [Related]
13. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
Imai E; Haneda M; Yamasaki T; Kobayashi F; Harada A; Ito S; Chan JC; Makino H
Hypertens Res; 2013 Dec; 36(12):1051-9. PubMed ID: 24026038
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y
Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526
[TBL] [Abstract][Full Text] [Related]
15. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Ferrari P; Marti HP; Pfister M; Frey FJ
J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
MacKinnon M; Shurraw S; Akbari A; Knoll GA; Jaffey J; Clark HD
Am J Kidney Dis; 2006 Jul; 48(1):8-20. PubMed ID: 16797382
[TBL] [Abstract][Full Text] [Related]
17. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
18. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
19. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials.
Cheng J; Zhang W; Zhang XH; He Q; Tao XJ; Chen JH
Int J Clin Pract; 2009 Jun; 63(6):880-8. PubMed ID: 19490198
[TBL] [Abstract][Full Text] [Related]
20. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy.
Sun LJ; Sun YN; Shan JP; Jiang GR
J Diabetes Investig; 2017 Jul; 8(4):609-618. PubMed ID: 28107779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
